Results 291 to 300 of about 85,787 (336)

Pancreatitis and PDAC: association and differentiation

Abdominal Radiology, 2019
The discrimination of mass-forming chronic pancreatitis (MFCP) from pancreatic ductal adenocarcinoma (PDAC) is a central diagnostic dilemma. It is important to differentiate these entities since they have markedly different prognoses and management.
Sherif B. Elsherif, Mayur Virarkar, Sanaz Javadi, Juan J. Ibarra-Rovira, Eric P. Tamm, Priya R. Bhosale   +5 more
openaire   +3 more sources

Zenocutuzumab Shines in PDAC

Cancer Discovery, 2021
Abstract Zenocutuzumab, an investigational bispecific antibody, has shown early efficacy in an ongoing phase I/II study of patients with tumors harboring NRG1 fusions. The data so far appear particularly promising in NRG1 fusion–positive pancreatic ductal adenocarcinoma, which tends to occur in younger patients.
openaire   +2 more sources

Overcoming Immunotherapeutic Resistance in PDAC: SIRPα-CD47 blockade.

Pharmacological Research, 2022
A daily increase in the number of new cases of pancreatic ductal adenocarcinoma remains an issue of contention in cancer research. The data revealed that a global cumulated case of about 500, 000 have been reported. This has made PDAC the fourteenth most
A. Alausa, Khadijat Ayodeji Lawal, O. Babatunde, E. Obiwulu, Olajumoke Christianah Oladokun, O. Fadahunsi, Ugwu Obiora Celestine, E. Moses, Akaniro Ifunanya Rejoice, P. Adegbola   +9 more
semanticscholar   +1 more source

Unlocking PDAC initiation with AP-1

Nature Cancer, 2021
Chronic pancreatitis is a risk factor for pancreatic cancer; however, the mechanisms underlying cellular susceptibility to oncogenic transformation are complex. A recent study reports a damage-associated progenitor cell state, controlled by the transcription factors KLF5 and members of the AP-1 family, that initiates tumorigenesis in mouse models of ...
Lindsay M. LaFave, Jason D. Buenrostro
openaire   +2 more sources

Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.

International Immunopharmacology, 2021
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest solid tumors with a high mortality rate and poor survival rate. Depending on the tumor stage, PDAC is either treated by resection surgery, chemotherapies, or radiotherapies.
Kanan Panchal, R. Sahoo, U. Gupta, Akash Chaurasiya   +3 more
semanticscholar   +1 more source

Broadening Diversity in PDAC Trials

Cancer Discovery, 2021
Abstract Findings from a simulated pancreatic cancer trial indicate that some common eligibility criteria, including infectious comorbidities, disproportionately disqualify more Black than white patients from being enrolled. The researchers proposed alternative criteria, showing that the changes could eliminate the imbalance in ...
openaire   +2 more sources

MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

Nature
Intratumour heterogeneity and phenotypic plasticity drive tumour progression and therapy resistance1,2. Oncogene dosage variation contributes to cell-state transitions and phenotypic heterogeneity3, thereby providing a substrate for somatic evolution ...
Elena Fiorini, A. Malinova, Daniel Schreyer, Davide Pasini, M. Bevere, Giorgia Alessio, D. Rosa, Sabrina D'Agosto, Luca Azzolin, Salvatore Milite, S. Andreani, F. Lupo, L. Veghini, Sonia Grimaldi, S. Pedron, Monica Castellucci, C. Nourse, R. Salvia, G. Malleo, A. Ruzzenente, A. Guglielmi, M. Milella, R. Lawlor, C. Luchini, A. Agostini, Carmine Carbone, Christian Pilarsky, A. Sottoriva, Aldo Scarpa, D. Tuveson, Peter Bailey, V. Corbo   +31 more
semanticscholar   +1 more source